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INTRODUCTION 
Laparoscopy is a surgical procedure in which a fiber optic instrument 
inserted through the abdominal wall to view the organs in the abdomen or 
permits surgery.  Also called minimally invasive surgery or keyhole surgery.  
They are performed far from their location through small incision elsewhere 
in the body. 
Introduced in 1970, laparoscopy has undergone various advancement 
to do even major surgeries. 
Laparoscopic surgeries has become recent trend in the surgical field 
aim to achieve a satisfactory therapeutic result while minimizing the 
traumatic and metabolic stress.  Advantages of Laparoscopic surgical 
procedures include less tissue trauma, smaller incisional sites, lower risks of 
wound complications, reduced postoperative pain, complications, shorter 
hospital stay, more rapid return to normal activities, and cost savings. 
Laparoscopy requeires the establishment of pnemoperitoneum in order 
to provoide adequate surgical exposure and maintain operative freedom.  This 
insufflation of carbon dioxide can lead to various physiological changes.  An 
emerging body of data adresses the hemodynamic, respiratory, 
immunological and stress response related to the pnemoperitoneum. 
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The physiologic changes associated with laparoscopy include those 
associated with tilting the patient to facilitate instrumentation, surgical 
exposure, the pressure effects of instilled gas into a closed cavity, and the 
systemic effects of the gas, almost universally, CO2 instilled (absorbed or 
embolized). 
Cardiovascular changes include increase in mean arterial pressure with 
no significant change in heart rate, decrease in cardiac output (10% to 30%),  
and increase in systemic vascular resistance.  These vasopressor responses 
are due to hypercarbia-induced release of catecholamines,  vasopressin, or 
both. 
The pneumoperitoneum and its consequent hemodynamic changes can 
be attenuated by pharmacological agents such as nitroglycerine, β blocker, 
and opioids, to provide hemodynamic stability during pneumoperitoneum,  
but they have their own disadvantages.  
Clonidine, a selective α-2 adrenergic receptor agonist, has shown 
promising results for attenuation of hemodynamic response associated with 
laparoscopic surgery.  Clonidine causes a fall in the heart rate and blood 
pressure along with decreased systemic vascular resistance and cardiac 
output.   
Magnesium blocks release of catecholamines from both adrenergic 
nerve terminals and adrenal gland.  Magnesium also produces vasodilation by 
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acting directly on blood vessels.  In high doses, it attenuates vasopressin-
mediated vasoconstriction.  
This study was designed in a prospective, randomized, double-blinded 
fashion to compare the efficacy of intravenously administered clonidine and 
magnesium sulfate on hemodynamic stress response during laparoscopic 
surgeries.   
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AIM OF THE STUDY 
 The aim of this study was to compare the intravenously administered 
clonidine and magnesium sulfate on hemodynamic responses during 
laparoscopic surgeries in terms of  
1. Heart rate 
2. Systolic blood pressure 
3. Diastolic blood pressure 
4. Mean arterial pressure 
5. Level of sedation on recovery 
6. Adverse effects 
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PHYSIOLOGICAL EFFECTS IN LAPAROSCOPIC SURGERIES 
 
The physiologic effects of carbon dioxide insufflation into an 
endocavity combined with various positioning causes a major impact on 
cardiopulmonary function that complicates anesthetic management.   
In earlier days higher intra-abdominal pressure (>20 mm Hg) were 
used and they observed many serious complications.  After 1990 
pneumoperitoneum using low intra-abdominal pressure (<15 mm Hg) was 
used in modern anesthesia techniques.   
 
PNEUMOPERITONEUM 
Hemodynamic Problems during Laparoscopy 
Hemodynamic changes observed during laparoscopy result from the 
combined effects of pneumoperitoneum, patient position, anesthesia, and 
hypercapnia from the absorbed CO2.  In addition to these pathophysiologic 
changes, reflex increases of vagal tone and arrhythmias can also develop. 
 
Hemodynamic Repercussions of Pneumoperitoneum in Healthy Patients  
Normal intra-abdominal pressure ranges from  zero to 5 mm Hg, but 
for better visualization of the operating field intra-abdominal pressure should  
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be maintained around 15 to 20 mm Hg.  Increases in intra-abdominal pressure 
above 10 mm Hg are clinically significant, and above 15 mm Hg can result 
in an abdominal compartment syndrome, which affects multiple organ 
systems.  The cardiovascular manifestations understood via the following 
simple relationship, which expresses the determinants of blood pressure: 
 
Mean Arterial Pressure (MAP) = Cardiac Output (CO) x  Systemic Vascular 
Resistance (SVR) 
Peritoneal insufflation to intra-abdominal pressure higher than 
10 mm Hg induces significant alterations of hemodynamics.  These 
disturbances characterized by decreases in cardiac output, increased arterial 
pressures, and elevation of systemic and pulmonary vascular resistance.  
Heart rates remain unchanged or increased only slightly.  The decrease in 
cardiac output is proportional to the increase in intra-abdominal pressure.  
Cardiac output also been reported to be increased or unchanged during 
pneumoperitoneum.  These discrepancies caused by differences in rates of 
CO2 insufflation, intra-abdominal pressure, steepness of patient tilt, time 
intervals between insufflation and collection of data, techniques used to 
assess hemodynamics, and anesthetic techniques.  However, the cardiac 
output reduced to 10% to 30% during peritoneal insufflation whether the 
patient placed in the head-down or head-up position.    Cardiac output, which 
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decrease shortly after the beginning of the peritoneal insufflation, 
subsequently increase, probably because of surgical stress.  Hemodynamic 
perturbations occur mainly at the beginning of peritoneal insufflation. 
 The increase in systemic vascular resistance mediated by mechanical 
and neurohumoral factors.  The return of hemodynamic parameters to 
baseline values is gradual, taking several minutes, suggesting the involvement 
of neurohumoral factors like catecholamines, renin-angiotensin system and 
vasopressin released during pneumoperitoneum contribute to increasing the 
afterload ultimately leads to increased cardiac work load.  Consequently, 
myocardial ischemia may result. 
 Initially, owing to autotransfusion of pooled blood from the splanchnic 
circulation, there is an increase in the circulating blood volume, resulting in 
an increase in venous return and cardiac output.  However, further increases 
in the intra-abdominal pressure result in the compression of the inferior vena 
cava, reduction in venous return and subsequent decrease in cardiac output. 
Further increase in intra-abdominal pressure decrease cardiac output 
with a subsequent fall in blood pressure, an effect more pronounced in 
patients who are hypovolemic or have cardiovascular disease.  
 
 
10 
 
Physiological effects of pneumoperitoneum 
Cardiovascular 
    IAP < 10 mm Hg ↑ VR ⟶ ↑ CO 
    IAP 10–20 mm Hg ↑ IAP ⟶ ↓ VR ⟶ ↓ CO 
 ↑ IAP ⟶ ↑ SVR 
 BP = ↓ CO × ↑↑ SVR 
 ↔↑ BP 
    IAP > 20 mm Hg ↓↓ VR ⟶ ↓↓↓ CO 
 ↓ BP 
Respiratory 
    Lung volumes esp FRC ↓ 
    Airway resistance ↑ 
    Pulmonary compliance ↓ 
    Airway pressure ↑ 
    Risk of barotrauma ↑ 
    V/Q mismatch ↑ 
Renal 
    Renal function ↓ 
Gastrointestinal 
    Risk of regurgitation ↑ 
Neurological  
    ICP ↔↑ 
CPP ↔↓ 
IAP, intra-abdominal pressure; VR, venous return; CO, cardiac output; SVR, 
systemic vascular resistance; BP, blood pressure; FRC, functional resistance 
capacity; ICP, intracranial pressure; CPP, cerebral perfusion pressure. 
 
Cardiac Arrhythmias during Laparoscopy  
Reflex increases of vagal tone may result from sudden stretching of the 
peritoneum and during electrocoagulation.  Bradycardia, cardiac arrhythmias, 
and asystole can develop.  Vagal stimulation accentuated if the level of 
anesthesia is too superficial or if the patient is taking β-blocking drugs.  These 
events are easily and quickly reversible.  Treatment consists of interruption 
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of insufflation, atropine administration, and deepening of anesthesia after 
recovery of the heart rate. 
 
Ventilatory and Respiratory Changes during Laparoscopy 
Intraperitoneal insufflation of carbon dioxide, the currently routine 
technique to create pneumoperitoneum for laparoscopy, results in ventilatory 
and respiratory changes and cause four principal respiratory complications: 
CO2 subcutaneous emphysema, pneumothorax, endobronchial intubation, 
and gas embolism. 
 
Ventilatory Changes 
Pneumoperitoneum decreases thoracopulmonary compliance by 30% 
to 50% in healthy and obese patients.  Reduction in functional residual 
capacity and development of atelectasis due to elevation of the diaphragm and 
changes in the distribution of pulmonary ventilation and perfusion from 
increased airway pressure is expected.   
However, increasing intra-abdominal pressure to 14 mm Hg with the 
patient in a 10 to 20 degree head-up or head-down position does not 
significantly modify either physiologic dead space or shunt in patients 
without cardiovascular problems. 
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Increase in the Partial Pressure of Arterial Carbon Dioxide 
During uneventful CO2 pneumoperitoneum, the PaCO2 progressively 
increases to reach a plateau, after 15 to 30 minutes of the beginning of CO2 
insufflation, patients under controlled mechanical ventilation during surgeries 
in the Trendelenburg position or in the head-up position.   
Any significant increase in PaCO2 after this period requires a search 
for a cause independent or related to CO2 insufflation, such as CO2 
subcutaneous emphysema.  The increase in PaCO2 depends on the intra-
abdominal pressure.   
 
CO2 Subcutaneous Emphysema.  
CO2 subcutaneous emphysema can develop as a complication of 
accidental extra peritoneal insufflation, but also considered as an unavoidable 
side effect of certain laparoscopic surgical procedures that require intentional 
extra peritoneal insufflation, such as inguinal hernia repair, renal surgery, and 
pelvic lymphadenectomy.   
During laparoscopic fundoplication for hiatal hernia repair, the opening 
of the peritoneum overlying the diaphragmatic hiatus allows passage of CO2 
under pressure through the mediastinum to the cervicocephalic region.  In this 
case, interrupt the laparoscopy to allow CO2 elimination and can be resumed 
after correction of hypercapnia using a lower insufflation pressure.  
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Pneumothorax, Pneumoperitoneum, Penuemopericardium 
Movement of gas during the creation of a pneumoperitoneum produce 
pneumomediastinum, unilateral and bilateral pneumothoraces, and 
Pneumopericardium.  Defects in the diaphragm or weak points in the aortic 
and esophageal hiatus may allow gas passage into the thorax.  
Pneumothoraces may also develop secondary to pleural tears during 
laparoscopic surgical procedures at the level of the gastroesophageal junction 
(e.g., fundoplication for hiatal hernia).  Although opening of peritoneopleural 
ducts is associated with mainly right-sided pneumothoraces, the 
pneumothorax associated with fundoplication is more frequently in the left 
side of the chest. 
When capnothorax develops during laparoscopy, treatment with 
positive end-expiratory pressure (PEEP) is an alternative to chest tube 
placement.  In contrast, if the pneumothorax is secondary to rupture of 
preexisting bullae, PEEP must not applied and thoracocentesis is mandatory. 
Endobronchial intubation  
Cephalad displacement of the diaphragm during pneumoperitoneum 
results in cephalad movement of the carina,  potentially leading to an 
endobronchial intubation. This complication results in a decrease in the 
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 oxygen saturation as measured by pulse oximetry (Spo2) associated with an 
increase in plateau airway pressure. 
Gas (CO2) Embolism 
It is the rare, most feared and dangerous complication of laparoscopy.  
Intravascular injection of gas may follow direct needle or trocar placement 
into a vessel, or it may occur because of gas insufflation into an abdominal 
organ.  This complication develops principally during the induction of 
pneumoperitoneum, particularly in patients with previous abdominal surgery.  
Gas embolism may also occur later during surgery.   
Treatment: Immediate cessation of insufflation, stop nitrous oxide, 
release of the pneumoperitoneum, steep head-down, left lateral decubitus 
position, Hyperventilation, central venous or pulmonary artery catheter, 
Cardiopulmonary resuscitation, Cardiopulmonary bypass and Hyperbaric 
oxygen treatment. 
 
Renal 
Pneumoperitoneum at pressure above 10 mmHg during laparoscopic 
surgery produces transient oliguria, reduced glomerular filtration rate and 
reduced renal blood flow.  Factors that may affect renal function during 
pneumoperitoneum include direct compression of the renal parenchyma and 
renal vein, increased resistance in the renal vasculature, and release of 
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vasoconstrictors, such as vasopressin, angiotensin II, catecholamines, and 
endothelin (ET)-1.  
 
Risk of Aspiration of Gastric Contents  
Patients undergoing laparoscopy are considered to be at risk for acid 
aspiration syndrome.  The increased intra-abdominal pressure results in 
changes of the lower esophageal sphincter that allow maintenance of the 
pressure gradient across the gastroesophageal junction and that may therefore 
reduce the risk of regurgitation.  Furthermore, the head-down position 
prevents any aspiration.   
 
Neurological 
Pneumoperitoneum during laparoscopic surgery also has the potential 
to increase cerebral blood flow (CBF), intracranial pressure, and intraocular 
pressure due to the increased PaCO2 caused by absorption of CO2 from the 
peritoneal cavity.  The creation of pneumoperitoneum during laparoscopic 
surgery elevates intra cranial pressure because increased the abdominal 
pressure obstructs venous return from the lumbar venous plexus. 
Pneumoperitoneum also increases cerebral blood flow due to an increase in 
PaCO2 and an increase in catecholamine release independent of PaCO2. 
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Metabolic Response 
Metabolic acidosis from CO2 absorption is the primary change with 
laparoscopy.  Systemic CO2 absorption and its metabolic consequences differ 
depending on the patient's respiratory status, since the lung eliminates 
absorbed CO2 buffered by the blood.   
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Physiological effects of Positioning 
 
During laparoscopy, the patient is placed in a variety of positions in 
order to maximize the surgical visual field and facilitate instrumentation.  The 
head-down (Trendelenburg) position is commonly used in appendicectomy, 
gynecological operations, prostatectomy, and colorectal procedures.  The 
steep head-down tilt is frequently used for laparoscopic gynecologic and 
urologic procedures.  The head-up position (reverse Trendelenburg) used for 
cholecystectomy, invasive urological surgery and gastric bypass surgery.  The 
tilting of a patient during laparoscopy results in important physiologic 
responses and potential serious complications.   
 In normotensive subjects, the head-down position results in an increase 
in central venous pressure and cardiac output.  The baroreceptor reflex 
response to increased hydrostatic pressure consists of systemic vasodilation 
and bradycardia.   
However, central blood volume and pressure changes are greater in 
patients with coronary artery disease, particularly in those with  poor 
ventricular function, leading to potentially deleterious increased myocardial 
oxygen demand.   
The Trendelenburg position may also affect the cerebral circulation, 
particularly in case of low intracranial compliance and result in elevation of  
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the intraocular venous pressure.  Although the intravascular pressure 
increases in the upper torso, the head-down position decreases transmural 
pressures in the pelvic viscera, reducing blood loss but increasing the risk of 
gas embolism. 
With the head-up position, a decrease in cardiac output and mean 
arterial pressure results from the reduction in venous return.  This decrease in 
cardiac output compounds the hemodynamic changes induced by 
pneumoperitoneum.  The steeper the tilt, the greater the fall in cardiac output. 
Venous stasis in the legs occur during the head-up position and it is 
aggravated by the lithotomy position.  As pneumoperitoneum further 
increases blood pooling in the legs, any additional factor contributing to 
circulatory dysfunction should be avoided.  The legs must be freely supported 
and not tightly strapped, and there should be no pressure on the popliteal 
space. 
Physiological effects of positioning 
 Trendelenburg Reverse Trendelenburg 
Cardiovascular 
    VR ↑ ↓ 
    CO ↑ ↓ 
    BP ↔ ↓ 
Respiratory 
    Lung volumes ↓ ↔ 
    V/Q mismatch ↑ ↔ 
    Atelectasis ↑ ↔ 
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Physiological effects of gas absorption 
Carbon dioxide is the most frequently used gas for insufflation of the 
abdomen, as it is colourless, highly soluble, non-toxic, non-flammable and 
has the greatest margin of safety.  It is absorbed readily from the peritoneum, 
causing an increase in PaCO2.  This has direct, as well as indirect (by raising 
catecholamine levels), effects on the cardiovascular system.  Increased 
cardiac contractility, tachycardia, and reduction in diastolic filling causes 
decreased myocardial oxygen supply to demand ratio and greater risk of 
myocardial ischemia. 
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PHARMACOLOGY OF CLONIDINE 
 
Clonidine, an Imidazoline derivative, synthesized in the early 1960s 
and produces vasoconstriction, mediated by α2- receptors. 
CHEMISTRY 
C9H9N3Cl2.HCl 
 
N-(2, 6-Dichlorophenyl)-4,5-dihydro-1H-imidazol-2-amine 
 
PHARMACOLOGY 
Mechanism of action 
Clonidine is a partial agonist at α-adrenoceptors both within the central 
nervous system and in the periphery.  It is more specific for α2-adrenoceptors 
than for α1-adrenoceptors with a ratio of affinities at these sites of 
approximately 220:1.  Within the central nervous system, α2-adrenoceptors 
are located both presynaptically on terminals of neurons and postsynaptically 
on nor-adrenergic neurons.  It is likely that clonidine acts at all central α2-
receptors, stimulation of which is associated with decreased neuronal 
excitability and inhibition of membrane – bound adenylate cyclase. 
High concentrations of clonidine may stimulate central α1-
adrenoceptors enhancing neuronal excitability.  Stimulation of peripheral 
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presynaptic α2-adrenoceptors on postganglionic noradrenergic or cholinergic 
neurons by clonidine contributes to reduced saliva flow, reduced intestinal 
motor activity and gastric acid secretion, and bradycardia. 
Endocrine and metabolic effects are apparently mediated by α2-
adrenoceptor.  Clonidine inhibits insulin secretion from the pancreatic β cell 
possibly via a α2A receptor.  The pressor effect of high doses of clonidine is 
due to peripheral vasoconstriction mediated by stimulation of postsynaptic α1 
and α2-adrenoceptors on vascular smooth muscle. 
 
The Imidazoline receptor 
Imidazoline receptors include three subtypes (I1, I2 and I3), and are 
widely distributed in the body, including the central nervous system.  
Clonidine, as an imidazoline binds to these imidazoline receptors, in addition 
to its well-described binding to α2-receptors.  Data suggest that imidazoline 
receptors make only a minor contribution to the ability of clonidine to inhibit 
norepinephrine release, while the main contribution to the action of clonidine 
is via α2-receptors. 
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PHARMACOKINETICS 
Clonidine is well absorbed after oral administration, and its 
bioavailability is nearly 100%, with peak concentrations in plasma and the 
maximal hypotensive effect observed 1 to 3 hours after an oral dose.  
A transdermal delivery patch, an alternative to oral therapy permits 
continuous administration of clonidine.  The drug released at an 
approximately constant rate for a week, requiring 3 or 4 days to reach steady-
state concentrations in plasma.  
When the patch is removed, plasma concentration remain stable for 
about 8 hours and then decline gradually over a period of several days, this 
decrease in concentration is associated with a rise in blood pressure.  
Clonidine crosses the placenta and distributes into breast milk.  
Distribution t ½   : 11 ± 9 minutes 
Elimination t ½   : 9 ± 2 hours 
Volume of distribution : 2.1 ± 0.4 L/kg 
Plasma protein binding : 20-40 % in vitro 
Excretion  : 70% of the dose, mainly in the form of    
unchanged parent drug (40-60%) in urine. 
PHARMACOLOGICAL ACTIONS 
Cardiovascular Actions 
The major pharmacological effects of clonidine involve changes in 
blood pressure and heart rate, although the drug has a variety of other 
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important actions.  Intravenous infusions of clonidine cause an acute rise in 
blood pressure, apparently because of the activation of postsynaptic α2- 
receptors in vascular smooth muscle.  Acute oral or intravenous 
administration of clonidine causes a dose-dependent fall in blood pressure 
and heart rate in both the supine and erect positions, with the orthostatic 
response being more prominent.  
Respiration 
 α2 agonists have minimal depressant effect on ventilation and do not 
potentiate ventilatory depressant effects of opioids. 
 
ADVERSE EFFECTS 
1. Drowsiness, dryness of mouth, dryness of nasal mucosa and eyes.  
Weakness, fatigue, headache, and withdrawal syndrome. 
2. Cardiovascular: Bradycardia, hypotension, syncope, congestive heart 
failure, sinus node arrest, junctional bradycardia, high degree atrio 
ventricular block, and arrhythmias. 
3. Central Nervous system: Nervousness, agitation, mental depression, 
insomnia, vivid dreams or nightmares, anxiety, visual and auditory 
hallucinations. 
4. Skin rash: Angioneurotic edema, pruritus, urticaria, and alopecia. 
5. Gastro intestinal tract:  Nausea and vomiting, anorexia. 
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6. Genitourinary:  Decreased sexual activity, impotence, and loss of 
libido. 
7. Hematological : Thrombocytopenia  
8. Metabolic : Weight gain and gynacomastia 
 
PRECAUTIONS 
1. Clonidine to be used with caution in patients with cerebrovascular 
disease, ischemic heart disease including myocardial infarction, 
renal impairment, occlusive peripheral vascular disorders such as 
Raynaud’s disease, or those with a history of depression. 
2. Possible transient pressor effect especially in patients already 
receiving other antihypertensive.  
3. Rebound hypertension, beta blockers may exacerbate the rebound 
hypertension 
4. Symptoms of increased catecholamine release such as agitation, 
sweating, tachycardia, headache, and nausea may occur.  
5. Clonidine hydrochloride has been associated with acute attacks of 
porphyria and considered unsafe in porphyric patients. 
 
Contraindications 
Sino-atrial node disease (Sick sinus syndrome) 
Atrioventricular node disease. 
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DRUG INTERACTIONS 
Potentially Hazardous Interactions 
1. Central nervous depressants:  
Hypnosedatives, antihistamines and alcohol may cause 
excessive drowsiness in patients treated with clonidine. 
2. β-Adrenoceptor antagonists:  
In patients receiving non-cardioselective β-blockers, the 
rebound rise of blood pressure following clonidine-withdrawal 
may be more marked due to unopposed α-adrenoceptor mediated 
vasoconstriction. 
3. Antipsychotics:  
Acute severe hypotension observed following concomitant 
administration of clonidine and chlorpromazine or haloperidol. 
4. Tricyclic and other antidepressants:  
Attenuate of the hypotensive effect of clonidine by desipramine.  
Other studies have failed to show any significant interaction 
between clonidine and amitriptyline, imipramine, or mianserin. 
5. α-Adrenergic antagonists:  
The effects of clonidine may be antagonized by centrally 
acting α-blockers such as phentolamine, tolazoline and 
phenoxybenzamine. 
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Potentially Useful Interactions 
1. Diuretics and/or vasodilators used in combination with clonidine to 
enhance its hypotensive effects.  Diuretics will counteract any 
tendency to fluid retention. 
2. Clonidine may substitute for β-blockers in opposing the reflex 
cardiac stimulation following administration of vasodilators such as 
hydralazine or nifedipine. 
 
ANAESTHETIC USES 
1. Premedication: Acts on locus ceruleus produces sedation.  In addition, 
got an anaesthesia sparing effect. 
2. Control of hemodynamics: It attenuates the haemodynamic response 
during laryngoscopy, intubation, and laparoscopic surgeries  
3. Epidural: It acts as a sole agent or in combination with opioids or local 
anaesthetics to provide excellent analgesia 
4. In Labour analgesia 
5. Spinal: With local anaesthetics clonidine improve the quality and 
duration of the block, minimize the tourniquet pain during lower limb 
surgery, and prevents shivering. 
6. Caudal: With local anaesthetics increases the duration of anaesthesia 
and analgesia 2 or 3 times without hemodynamic side effects. 
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7. Peripheral nerve blocks:  Prolongs the duration of anaesthesia and 
analgesia with local anaesthetics in a dose of 75-150µg. 
8. Bier’s Block 
9. Intra articular analgesia 
CLONIDINE DOSAGE FORMS 
Oral Tablets Clonidine tablet  0.1, 0.2 and 0.3 mg 
Transdermal patches Clonidine – TTS  0.1, 0.2 and 0.3 G, 3mg/24 Hrs. 
Combination 
Tablets 
Clonidine and 
chlorthalidone 
0.1 mg clonidine/15 mg 
chlorthalidone 
0.2 mg clonidine/15 mg 
chlorthalidone 
0.3 Mg clonidine /15 mg 
chlorthalidone 
Injection Cloneon, duration 500 mcg/ml, 100 mcg/ml as 
ml 10 ml vials 
 
Overdosage and Treatment  
 There is no specific antidote for clonidine over dosage.  Supportive 
measures like atropine, ephedrine and intravenous fluids is enough.  For 
hypertensive crisis intravenous furosemide, diazoxide, phentolamine used.  
Yohimbine partially reverses the analgesia and sedation but not the BP and 
heart rate changes produced by the epidural clonidine. 
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Pharmacology of Magnesium 
 
Magnesium (Mg++) is an important cofactor for enzymatic reactions 
and plays an important role in neurochemical transmission and muscular 
excitability.  
As a nutritional adjunct in hyperalimentation, the precise mechanism 
of action for magnesium is uncertain.  Early symptoms of hypomagnesemia 
(less than 1.5 mEq/L) may develop within 3 to 4 days or weeks.  Predominant 
effects are neurological, e.g., muscle irritability, clonic twitching and tremors.  
Hypocalcemia and hypokalemia often follow low serum levels of magnesium.  
Large stores of magnesium present are intracellularly and in the bones of 
adults, these stores often mobilized sufficiently to maintain plasma levels.   
Mechanism of Action 
1. A competitive antagonism on hippocampal presynaptic calcium 
channels that regulate neurotransmitter release in the central nervous 
system. 
2. Attenuation of catecholamine release from the adrenal medulla and 
calcium antagonistic effects on vascular smooth muscle cells may 
contribute to the anaesthetic effects of magnesium. 
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3. Neuromuscular blockade: the inhibition of calcium-mediated release of 
acetylcholine from the presynaptic nerve terminal at the neuromuscular 
junction plays an important role.   
4. Anticonvulsive: Blocks neuromuscular transmission and decreases the 
amount of acetylcholine liberated at the end plate by the motor nerve 
impulse.  
5. Antinociceptive effects: By Inhibition of calcium influx and 
antagonism of NMDA receptors. 
6. Central sensitization:  Attenuate or even prevent central sensitization 
after peripheral tissue injury or inflammation because of inhibition of 
dorsal horn NMDA receptors.  
7. Central nervous system: Depressant effect 
 
Pharmacokinetics 
 Normal plasma magnesium levels range from 1.5 to 2.5 or 3.0 mEq/L.  As 
plasma magnesium rises above 4 mEq/L, the deep tendon reflexes are first 
decreased and then disappear as the plasma level approaches 10 mEq/L.  At 
this level, respiratory paralysis may occur.  Heart block also may occur at this 
or lower plasma levels of magnesium. 
 
With intravenous administration, the onset of anticonvulsant action is 
immediate and lasts about 30 minutes.  Following intramuscular 
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administration, the onset of action occurs in about 1 hour and persists for 3 to 
4 hours.  Effective anticonvulsant serum levels range from 2.5 or 3.0 to 7.5 
mEq/L. Magnesium excreted solely by the kidney at a rate proportional to the 
plasma concentration and glomerular filtration. 
 
Pharmacodynamics 
Indications and Clinical Uses:  
1. Deficiency: For replacement therapy in magnesium deficiency, 
especially in acute hypomagnesemia.  
2. Total parenteral nutrition:  magnesium sulfate may be added to the 
nutrient admixture to correct and prevent hypomagnesemia. 
3. Anticonvulsant: Magnesium sulfate injection is given as a parenteral 
anticonvulsant for the prevention and control of seizures  in pregnancy.   
4. Antihypertensive: Magnesium sulfate injection used to control 
hypertension, encephalopathy, and convulsions associated with acute 
nephritis in children.  
5. Laparoscopic surgeries: Attenuates the stress response by blocking 
the catecholamine release 
 
Contra-Indications:  
Intravenous magnesium given to mothers with toxemia of pregnancy 
during the 2 hours preceding delivery.  
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Adverse Reactions:  
1. Magnesium intoxication: flushing, sweating, hypotension, 
depressed reflexes, flaccid paralysis, hypothermia, circulatory 
collapse, cardiac and central nervous system depression proceeding 
to respiratory paralysis.  
2. Hypocalcemia:  with signs of tetany secondary to magnesium 
sulfate therapy. 
3. Central nervous system: Drowsiness and loss of muscle tone 
 
Precautions:  
Because magnesium excreted from the body exclusively by the 
kidneys, the drug should be used with caution in patients with renal 
impairment.  
Monitoring serum magnesium levels and the patient's clinical status is 
essential to avoid the consequences of over dosage in toxemia.  
Clinical indications of a safe dosage regimen include the presence of 
the patellar reflex (knee jerk), absence of respiratory depression 
(approximately 16 breaths or more/minute)  and urine output  at the level of 
100 mL every 4 hours.  
Serum magnesium levels usually sufficient to control convulsions 
range from 3 to 6 mg/100 mL (2.5 to 5.0 mEq/L).  
34 
 
Drug Interactions:  
CNS Depressants:  
When barbiturates, opiates, general anesthetics, or other CNS 
depressants administered concomitantly with magnesium sulfate, dosage of 
these agents carefully adjusted because of the additive central depressant 
effects. 
Neuromuscular Blocking Agents:  
Excessive neuromuscular blockade has occurred in patients receiving 
parenteral magnesium sulfate and a neuromuscular blocking agent. 
Cardiac Glycosides:  
Magnesium salts administered with extreme caution in digitalized 
patients. 
Symptoms and Treatment of Overdose:  
Disappearance of the patellar reflex is a useful clinical sign to detect 
the onset of magnesium intoxication.  
In adults, intravenous administration of 5 to 10 mEq of 10% calcium 
gluconate will usually reverse respiratory depression or heart block due to 
magnesium intoxication.  In extreme cases, peritoneal dialysis or 
hemodialysis may be required. 
Hypermagnesemia in the newborn may require resuscitation and 
assisted ventilation via endotracheal intubation or intermittent positive 
pressure ventilation, as well as intravenous calcium. 
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Table 1: Dosage and Administration 
Dosing Magnesium Sulfate, Adults 
Preeclampsia or eclampsia 4–6 g IV loading dose over 15–20 min (5 
min in severe cases), followed by 1–2 g IV 
continuous infusion or 4–5 g IM in each 
buttock every 4 h 
Torsades de Pointes arrhythmia 
 
Pulseless: 1–2 g IV over 5–20 min 
With pulse: 1–2 g IV over 5–60 min 
Asthma Life-threatening or severe exacerbation 
(unlabeled use): 2 g IV over 30–60 min 
Severe deficiency 1–2 g/h IV for 3–6 h, followed by 0.5–1 
g/h IV as needed 
Slow administration of IV magnesium sulfate is preferable in stable patients.  Renal 
impairment requires close monitoring for signs of hypermagnesemia. 
 
IM = intramuscular; IV = intravenous. 
Clinical Uses: 
Attenuation of Laparoscopic stress response 
Antihypertise 
Eclampsia:  
In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 
14grams of magnesium sulfate.  Intravenous dose of 4 to 5 g in 250 mL of 
5% Dextrose Injection or 0.9% Sodium Chloride Injection may be infused.   
Nephritic Seizures:  
In children with nephritic seizures, the 50% concentration diluted to a 
20% solution for intramuscular injection.  The dose for children is 20 to 40 
mg (0.1 to 0.2 mL of a 20% solution)/kg of body weight, administered 
intramuscular as needed, to control seizures.  
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REVIEW OF LITERATURE 
1. R.Uma et al30 did a randomized placebo controlled study to assess the 
effect of intravenous clonidine on intraoperative hemodynamics in 40 
patients who underwent elective laparoscopic cholecystectomy.  
Patients were randomized into 2 groups.  Group C received intravenous 
clonidine at a dose of 3 µg/kg over 15 minutes prior to induction and 
Group P received NS (Normal Saline).  Pulse rate and mean arterial 
pressure recorded prior to induction, 2 minutes after intubation, before 
pneumoperitoneum, 10 and 20 minutes after pneumoperitoneum and 
10 minutes after extubation.  They concluded that patients in Group C 
maintained greater intraoperative hemodynamic stability and there was 
significant decrease in pulse rate and mean arterial pressure in the 
clonidine group during pemoperitoneum and after extubation. 
(J.Pharm Biomed Sci.2013, Februalry; 27(27): 451-455) 
 
2. Mohua Sengupta et al32 designed a randomized double blind 
prospective trail to to evaluate the efficacy of clonidine in achieving 
haemodynamic stability in patients undergoing laparoscopic 
cholecystectomy.  Sixty patients, of both sex (31-60 yrs of age) 
undergoing elective laparoscopic cholecystectomy were randomly 
allocated equally in one of the two parallel groups: C and  P. Group C 
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received clonidine 1.5 μg /kg intravenously over a period of 15 minutes 
before induction followed by 1 μg/kg /hr by continuous intravenous 
infusion.  Group P received isotonic saline (0.9% ) in the same volume.  
Mean arterial pressure and heart rate in Group C was significantly less 
after intubation and throughout the period of pneumoperitonium.  No 
significant difference in the parameters of recovery observed between 
the two groups.  They concluded that clonidine improves intra and 
post- operative haemodynamic stability during laparoscopic surgery 
without prolonging recovery. 
(International Journal of Pharmaceutical, Chemical and 
Biological Sciences 2013, 3(3), 610-614 )  
3. Sudheer Rao et al31 have conducted a prospective, comparative, 2-Arm 
(Group), double-blind controlled study in 60 ASA grades I and II adult 
patients of either sex aged 20-60 years, scheduled to undergo 
laparoscopic cholecystectomy.  The subjects were assigned to one of 
the two groups by closed envelope method, namely Group C (clonidine 
3 μg/kg in 20 ml), and Group P (placebo - 20 ml normal saline).  
Loading dose of test drug diluted in 20 ml of normal saline or placebo, 
20 ml of normal saline were administered intravenously.  Thirty 
minutes after the end of the infusion of the test drug, anaesthesia was 
induced and intubated.  Demographic profile of 60 patients  were 
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compared between the two groups of patients, and no significant 
difference  found.  Mean heart rate varied from 71.91 ± 4.95 to 99.88 
± 2.83 beats per minute in Group P.  In Group C, it varied from 63.78 
± 1.07 to 86.38 ± 6.28 beats per minute.  Similarly, rise in mean arterial 
pressure (106.85 ± 8.36 vs. 86.00 ± 0.57 mm Hg) was more in Group 
P 15 min following pneumoperitoneum and after intubation (109.26 ± 
10.93 vs. 76.84 ± 4.32).  Incidence of intraoperative hypertension was 
34.3% in Group P (11 patients) that required treatment with 
intravenous infusion of 0.5 μg/kg/min injection nitroglycerine.  They 
concluded that Clonidine at a dose of 3 μg/kg administered 
intravenously before peritoneal insufflation with carbon dioxide 
attenuated the haemodynamic changes by reducing hormonal stress 
response and plasma cortisol concentration. 
 (Indian Journal of Anaesthesia January-February 2015) 
4. Jee D et al35 investigated whether intravenous magnesium sulphate 
attenuates the haemodynamic stress responses to pneumoperitoneum 
by changing neurohumoral responses during laparoscopic 
cholecystectomy.  Thirty-two patients undergoing laparoscopic 
cholecystectomy randomly assigned to two groups; the control group 
was given saline, and a magnesium group received magnesium 
sulphate 50 mg/kg immediately before pneumoperitoneum.  Arterial 
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pressure, heart rate, serum magnesium, plasma renin activity (PRA), 
and catecholamine, cortisol, and vasopressin levels measured.  Systolic 
and diastolic blood pressures were greater in the control group (P,0.05) 
than in the magnesium group at 10, 20, and 30 min post-
pneumoperitoneum.  Norepinephrine or epinephrine levels were higher 
in the control group than in the magnesium group.  In the control group, 
vasopressin levels were higher compared with the magnesium group.  
There were no significant differences between the groups in plasma 
renin activity and cortisol levels.  They concluded that intravenous 
magnesium sulphate before pneumoperitoneum attenuates arterial 
pressure increases during laparoscopic cholecystectomy 
(British Journal of Anaesthesia 2009; 103) 
 
5. Telci L et al38 conducted a randomized, placebo-controlled, double-
blind study to assess the effect of peroperatively administered 
intravenous magnesium sulphate on anaesthetic and analgesic 
requirements during total intravenous anaesthesia.  Eighty-one patients 
(36 women, 45 men) undergoing elective spinal surgery were included 
in one of two parallel groups.  The magnesium group received 
magnesium sulphate 30 mg/kg as a bolus before induction of 
anaesthesia and 10 mg/kg/hr  by continuous intravenous infusion 
during the operation period.  The same volume of isotonic saline was 
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administered to the control group.  Anaesthesia was maintained with 
propofol (administered according to the bispectral index) and 
remifentanil (adjusted according to heart rate and arterial blood 
pressure) infusions.  A significant reduction in hourly propofol 
consumption observed with magnesium administration.  The 
magnesium group required significantly less remifentanil (P<0.001) 
and vecuronium (P<0.001).  No side effects observed with magnesium 
administration.   They concluded that the administration of magnesium 
led to a significant reduction in the requirements for anaesthetic drugs 
during total intravenous anaesthesia with propofol, remifentanil and 
vecuronium.         
(British Journal of  Anaesthesia 2002 October) 
 
6. Nand Kishore Kalra et al29 conducted a randomized, double blinded, 
placebo controlled study to compare the effect of clonidine and 
magnesium sulfate in 120 patients undergoing elective laparoscopic 
cholecystectomy.  They were randomized into 4 groups of 30 each.  
Group K patients received 50 ml normal saline over a period of 15 min 
after induction and before pneumoperitoneum, group M patients 
received 50 mg/kg of magnesium sulfate in normal saline (total volume 
50 ml) over same time duration.  Group C1 patients received 1 μg/kg 
clonidine and group C2 1.5μg/kg clonidine respectively in normal 
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saline (total volume 50 ml).  Systolic blood pressure, Diastolic blood 
pressure and heart rate were recorded before induction (baseline value), 
at the end of infusions and every 5 min after pneumoperitoneum.  They 
concluded that the administration of magnesium sulfate 50mg/kg 
produces hemodynamic stability comparable to clonidine 1 µg/kg and 
clonidine in dose of 1.5 µg/kg blunts the hemodynamic response to 
pneumoperitoneum effectively. 
(Journal of Anaesthesiology Clinical Pharmacology;July-September 
2011;27; 3) 
7. Manjaree Mishra et al33 conducted  a study with Sixty patients aged 20-
65 years of ASA grade I and II undergoing laparoscopic 
cholecystectomy were randomized into 3 groups and given an infusion 
of clonidine (group I), nitroglycerin (group II), or normal saline 
solution (group III) after induction and before creation of 
pneumoperitoneum.  Heart rate, mean arterial blood pressure, end-tidal 
carbon dioxide, and intraocular pressure were monitored.  The mean 
and standard deviation of the parameters studied during the observation 
period were calculated for the 3 treatment groups and compared. They 
concluded that the statistically significant differences in heart rate were 
observed among the various groups, whereas comparisons of mean 
arterial pressure, intraocular pressure, and end-tidal carbon dioxide 
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showed statistically significant differences only between clonidine  and 
placebo and between nitroglycerine and placebo. 
(Journal of the Society of Laparoendoscopic Surgeons. 2014 Jul-Sep) 
 
8. Ray M et al34 were conducted a randomised, placebo-controlled, 
double-blind study designed to assess the effect of intravenous 
clonidine and magnesium sulphate on intraoperative haemodynamics, 
anaesthetic consumption and postoperative recovery.  Seventy-five 
patients undergoing elective upper limb orthopaedic surgery were 
randomised into three groups.  Group C received clonidine 3 μg/kg as 
a bolus before induction and 1μg/kg/hour by infusion intraopertively.  
Group M received magnesium sulphate 30 mg/kg as a bolus before 
induction and 10 mg/kg/hour by infusion.  Group P received same 
volume of isotonic saline.  Induction time, recovery time, and 
consumption of propofol as well as fentanyl citrate recorded.  Induction 
of anaesthesia was rapid with both clonidine and magnesium sulphate.  
Requirements of propofol and fentanyl were significantly less in Group 
C and Group M (P < 0.001).  Postoperative recovery was slower in 
Group M compared with other two groups (P < 0.001).  They 
concluded that perioperative use of both clonidine and magnesium 
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sulphate significantly reduced the consumption of propofol and 
fentanyl citrate.  Magnesium sulphate caused a delayed recovery. 
(Indian J Anaesth 2010 March- April) 
 
9. Altan A, et al36 have conducted a placebo-controlled, double-blind 
study to assess the effects of magnesium sulphate and clonidine on 
peroperative haemodynamics, propofol consumption and postoperative 
recovery.  Sixty ASA I-II patients undergoing spinal surgery 
randomized into three groups.  Group M received magnesium sulphate 
30 mg/kg as a bolus before induction and 10 mg/kg/h by infusion.  
Group CL received clonidine 3 µg/kg as a bolus before induction and 
2 µg/kg/h by infusion during the operation period.  The control group 
received isotonic solution (group CT). They observed that There was 
no statistical difference in heart rate and arterial blood pressure 
between the groups. The time for BIS to reach 60 was significantly 
shorter in group M and group CL (P<0.0001) but postoperative 
recovery was slower with magnesium sulphate compared with the 
clonidine and control groups (P<0.0001).  There was no statistical 
difference in heart rate and arterial blood pressure between the groups.  
Propofol requirements for induction and maintenance of anaesthesia 
were significantly lower with magnesium and clonidine (P<0.0001).  
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They concluded that Clonidine caused bradycardia and hypotension 
and magnesium sulphate caused delayed recovery, but used as adjuvant 
with careful management.  
(British Journal of Anesthesia 2005 April) 
 
10. Deepshikha C Tripathi  et al39 conducted a prospective, randomized, 
double-blind controlled to compare the effect of two different doses of 
intravenous clonidine premedication on hemodynamic stress response 
during laparoscopic cholecystectomy.  Patients were randomized to one 
of the three groups (n= 30). Group I received 100 ml of normal saline, 
while groups II and III received 1 μg/ kg and 2 μg/ kg of clonidine 
respectively, intravenously, in 100 ml of normal saline.  Hemodynamic 
variables (heart rate, systolic, diastolic, mean arterial pressure), SpO2, 
and sedation score were recorded at specific timings.  Mean arterial 
pressure above 20% from baseline was considered significant and 
treated with nitroglycerine.  In group I, there was a significant increase 
in hemodynamic variables during intubation, pneumoperitoneum and 
extubation (P<0.001). Clonidine given 1 μg/kg intravenous attenuated 
hemodynamic stress response to pneumoperitoneum (P<0.05).  They 
concluded that the Clonidine, 2 μg/ kg intravenously, 30 min before 
induction is safe and effective in preventing the hemodynamic stress 
response during laparoscopic cholecystectomy. 
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(Journal of Anaesth Clin Pharmacol 2011;27:475-80) 
  
 
11. Sunil Chiruvella  et al40 conducted a study to compared the effect of 
Clonidine versus Dexmedetomidine for Hemodynamic Stability during 
Laparoscopic Cholecystectomy. Group-C (clonidine group) received 
clonidine 1 μg/kg in normal saline and Group D (dexmedetomidine 
group) received dexmedetomidine 1 μg/kg in normal saline 
intravenously.  Total volume of the study drug was adjusted to 50 ml 
and administered over a period of 15 min before induction.  Mean heart 
rate was low for Group D. Four out of 29 patients (15%) in Group D 
required intravenous atropine due to bradycardia. Systolic arterial 
pressure was significantly lower in Group D, especially after 
intubation, at 30 minutes after pneumoperitoneum and after extubation. 
No significant episode of hypotension was found in any of the groups 
post pneumoperitoneum. None of the patient showed any evidence of 
ischemia or arrthymia intraoperatively. They concluded that 
Dexmedetomidine was more effective in attenuating hemodynamic 
response to pneumoperitoneum when compared with clonidine.  
However, with dexmedetomidine there are greater chances of 
developing hypotension and bradycardia. 
(Int J Sci Stud 2014;2(7):186-190.) 
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12. Gupta Kumkum et al41 conducted a prospective randomized double 
blind study to compare the effect of Premedication with clonidine 
versus fentanyl for intraoperative hemodynamic stability and recovery 
outcome during laparoscopic cholecystectomy under general 
anesthesia. Group C patients have received intravenous clonidine 
1μg/kg and Group F patients have received intravenous fentanyl 
2μg/kg 5 min before induction. Anesthetic and surgical techniques 
were standardized. All patients were assessed for intraoperative 
hemodynamic changes at specific time and postoperative recovery 
outcome. Premedication with clonidine or fentanyl has attenuated the 
hemodynamic responses of laryngoscopy and laparoscopy. Clonidine 
was superior to fentanyl for intraoperative hemodynamic stability. No 
significant differences in the postoperative recovery outcome were 
observed between the groups. Nausea, vomiting, shivering and 
respiratory depression were comparable between groups. They 
concluded that the Premedication with clonidine or fentanyl has 
effectively attenuated the intraoperative hemodynamic responses of 
laparoscopic cholecystectomy. 
(Anesth Essays Res 2013;7:29-33.) 
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13. Paul S et al37 investigated the efficacy of magnesium sulfate to prevent 
adverse hemodynamic response associated with pneumoperitoneum in 
patients undergoing laparoscopic cholecystectomy.  Sixty patients, of 
either sex (18‑65 years of age), undergoing elective laparoscopic 
cholecystectomy were randomly allocated in one of the two groups 
containing 30 patients each.  Group M received magnesium sulfate 30 
mg/kg intravenously as a bolus before pneumoperitoenum. Group C 
received same volume of 0.9% saline.  Mean arterial pressure and heart 
rate were significantly less throughout the period of 
pneumoperitoneum in patients of group M. Intravenous labetalol was 
required in 40% (12 out of 30) of the patients in group C to control 
intraoperative hypertension and it as clinically significant in 
comparison to group M. They concluded that Magnesium sulfate 
administered before pneumoperitoneum attenuates adverse 
hemodynamic response and provides hemodynamic stability during 
pneumoperitoneum created for laparoscopic surgery.   
(Anesthesia: Essays and Researches 2013 May-Aug) 
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MATERIALS AND METHODS 
  This is a double blinded prospective randomized study was conducted 
in the Thanjavur medical college, Thanjavur during the period 2014-2015. 
After obtaining institutional ethical committee approval and informed 
consent, 60 ASA physical status I and II subjects in the age group of 20-60 
years planned for elective laparoscopic surgeries with CO2 
pneumoperitoneum were enrolled in this study. They were randomly 
allocated to one of the two study groups, Group C (Clonidine group) and 
Group M (Magnesium group). 
 
Statistical test of significance  
 Comparison of parameters was done using One-Way ANOVA 
and categorical data was compared using Chi-square test. P Value 
<0.05 considered as statistically significant. 
 
Inclusion criteria 
1. ASA I and II 
2. Age group of 20-60 years 
3. Patients of both sex 
4. Patients posted for elective laparoscopic surgery 
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Exclusion criteria   
1. Patients who refuse to give informed written consent. 
2. Patients with systemic disorders like hypertension, diabetes mellitus, 
left ventricular failure, any degree of heart block, ischemic heart 
disease, aortic stenosis.  
3. Patients on calcium channel blockers, beta blockers, methyldopa, 
Tricyclic antidepressants, benzodiazepines, monamine oxidase 
inhibitors. 
4. Hypermagnesaemia 
 
Preanaesthetic evaluation 
All patients were kept on 6 hours starvation. Patients were premedicated 
with intravenous ranitidine 0.25 mg/kg, metoclopramide 0.15 mg/kg and 
glycopyrrolate 0.02 mg/kg intra muscularly in preoperative room 60 minutes 
before surgery.  
 
In the Operating room 
On arrival in the operation theater, monitors were connected (heart rate, 
NIBP, oxygen saturation, ECG) and baseline vital parameters like heart rate, 
systolic and diastolic blood pressure, and oxygen saturation were recorded. 
Fentanyl 2 µg/kg intravenous was given for analgesia.  After pre-oxygenation 
with 100% oxygen for 3 minutes. Induction agent propofol 2- 2.5 mg/ kg and 
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succinyl choline chloride 1- 2mg/kg given intravenously and intubated with 
appropriate size endotracheal tube. ETCO2 monitor were connected. 
 
 
Procedure 
Prefilled syringes with the test drugs was given to the anaesthesiologist 
with the instructions to give the test drug immediately after intubation.  
Group C Patients were given a solution containing clonidine 1.5 μg/kg 
(group C) in 50 ml of normal saline over a period of 15 min.  
Group M Patients were given a solution containing magnesium sulfate 
50 mg/kg in 50 ml of normal saline over a period of 15 min.  
Anesthesia was maintained with oxygen-nitrous oxide mixture (50:50) 
and intermittent positive pressure ventilation, Inj. vecuronium bromide 
0.08mg/ kg as loading dose and thereafter vecuronium bromide 0.02mg/kg as 
the intermittent boluses for maintenance was given.  The tidal volume and 
respiratory rate adjusted to maintain end tidal carbon dioxide between 35 and 
45 mm Hg.  During surgery, Ringer’s lactate was infused in accordance with 
maintenance volume requirements and blood loss.  CO2 pneumoperitoneum 
was created and intraabdominal pressure maintained at 14 mm Hg.  
Trendelenburg position was used for the laparoscopic appendicectomy  and 
Reverse trendelenburg position was used for the laparoscopic 
cholecystectomy. 
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Assessment of parameters 
 The parameters like Systolic blood pressure, Diastolic blood pressure, 
mean arterial Blood pressure, heart rate and SPO2 were recorded at the 
following point of time 
1. Prior to induction (baseline value)  
2. At the end of infusion  (P0) 
3. 5 min after pneumoperitoneum (P5) 
4. 10 min after pneumoperitoneum (P10)  
5. 20 min after pneumoperitoneum (P20) 
6. 30 min after pneumoperitoneum (P30)  
7. 40 min after pneumoperitoneum (P40)  
Patients were monitored for any adverse effects like bradycardia, and 
hypotension during intraoperative period. 
Neuromuscular block was reversed with intravenous neostigmine 0.05 
mg/kg and glycopyrrolate 0.02 mg/ kg and after adequate recovery, patient 
extubated.   
 
Adverse effects 
Immediately after the extubation the patients were monitored for 
nausea, vomiting, shivering and level of sedation assessed by Modified 
Ramsay sedation score. 
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Modified Ramsay sedation score 
Score Level of activity 
0 Paralyzed, unable to evaluate 
1 Awake 
2 Lightly sedated 
3 Moderately sedated, follows simple commands 
4 Deeply sedated, responds to non-painful stumuli  
5 Deeply sedated, responds only to painful stimuli 
6 Deeply sedated, unresponsive to painful stimuli 
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OBSERVATIONS AND RESULTS 
 This prospective double blinded randomized controlled study was done 
in 60 ASA I and II patients of either sex aged between 20-60 years, posted 
for elective laparoscopic surgeries under general anaesthesia.  The study was 
undertaken to compare the efficacy of intravenously administered clonidine 
and magnesium sulfate to attenuate the hemodynamic response during 
laparoscopic surgeries and the adverse effects. 
DEMOGRAPHIC CHARACTERISTICS OF STUDY POPULATION 
AGE 
 
Age wise distribution of study groups 
Study 
Group 
N Range 
(years) 
Mean ± Standard 
deviation  
P 
Value 
Significance 
C 30 20 – 60 40.23 ± 10.76 
0.919 
Not 
Significant M 30 20 – 60 43.10 ± 11.51 
Total 60 20 – 60 41.65 ± 11.14   
 
The age distribution was in the range of 20-60 years in Group C and 
Group M.  The P Value for mean age was not statistically significant. 
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WEIGHT 
Comparison of groups on basis of Mean body weight 
Study 
Group 
N Range 
(Kgs) 
Mean ± 
Standard 
deviation 
P Value Sinigicance 
C 30 40– 78 59.10 ± 13.21  
0.998 
 
Not significance M 30 42 – 78 60.42 ± 12.22 
Total 60 40 – 78 59.78 ± 12.61   
 
The weight distribution was in the range of 40-78 kgs in Group C and 
42-78 kgs Group M.   
The P Value for mean weight was not statistically significant. 
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ASA STATUS 
 
Comparison of groups on basis of ASA Status 
Study 
Group 
ASA 1 ASA 2 Total P Value Significance 
C 12 (40) 18 (60%) 30  
0.071 
 
Not significant M 12 (40) 18 (60%) 30 
Total 24 (16%) 36 (84%) 60   
 
No statistically significant difference observed in the ASA status among the 
groups. 
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Duration of the surgery 
Comparison of groups on basis of Duration of the surgery 
Study 
Group 
Mean ± Standard 
Deviation 
P Value Significance 
C 53.10 ± 5.88  
0.865 
 
Not significant M 52.87 ± 4.64 
Total 52.98 ± 5.25   
 
 
 The mean duration of the surgery in the group C was 53.1 and group 
M was 52.87.  The p value is 0.865 and statistically insignificant. 
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HEMODYNAMIC PROFILE 
HEART RATE 
 
Comparison of groups on basis of  Heart rate 
Heart rate 
(beats per 
minute) 
Group C n=30 
(Mean ± Standard 
deviation) 
Group M n=30 
(Mean ± Standard 
deviation) 
P Value Significance 
Base line 89.73 ± 10.77 90.57 ± 11.96 0.778 Not 
significant 
0 min 84.07 ± 10.87 85.43 ± 12.63 0.668 Not 
significant 
5 min 86.90 ± 10.78 90.73 ± 12.55 0.234 Not 
significant 
10 min 90.23 ± 10.77 95.90 ± 12.60 0.066 Not 
significant 
20 min 88.03 ± 10.65 93.13 ± 12.54 0.095 Not 
significant 
30 min 90.53 ± 10.94 95.57 ± 12.26 0.099 Not 
significant 
40 min 92.40 ± 11.05 97.07 ± 12.33 0.128 Not 
significant 
 
There was no statistically significant difference in the Heart rate status 
among the groups at any point of time during the study. 
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SYSTOLIC BLOOD PRESSURE 
 
Comparison of groups on basis of Mean systolic blood pressure 
SBP 
(mm Hg) 
Group C n=30 
(Mean ± Standard 
deviation) 
Group M n=30 
(Mean ± Standard 
deviation) 
P Value Significance 
Base line 117.40 ± 7.31 119.63 ± 8.24 0.271 
Not 
significant 
0 min 112.00 ± 8.46 114.63 ± 8.20 0.226 
Not 
Significant 
5 min 116.47 ± 9.10 120.17 ± 8.26 0.104 
Not 
significant 
10 min 119.67 ± 9.56 124.13 ± 8.42 0.600 
Not 
Significant 
20 min 116.83 ± 9.78 121.07 ± 8.69 0.820 
Not 
Significant 
30 min 118.20 ± 9.66 122.60 ± 8.67 0.068 
Not 
significant 
40 min 121.17 ± 10.19 125.53 ± 8.78 0.081 
Not 
Significant 
 
There was no statistically significant fall in systolic blood pressure is 
noted between the groups.  
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DIASTOLIC BP 
 
DBP Group C n=30 
(Mean ± Standard 
deviation) 
Group M n=30 
(Mean ± Standard 
deviation) 
P 
Value 
Significance 
Base 
line 
81.10 ± 5.96 80.07 ± 6.71 0.531 Not 
significant 
0 min 76.23 ± 5.63 73.47 ± 6.70 0.089 Not 
significant 
5 min 79.63 ± 5.64 77.33 ± 6.65 0.154 Not 
significant 
10 min 81.63 ± 5.85 80.27 ± 6.49 0.395 Not 
significant 
20 min 83.70 ± 6.05 83.13 ± 6.45 0.727 Not 
Significant 
30 min 81.73 ± 6.11 79.97 ± 6.62 0.287 Not 
Significant 
40 min 83.17 ± 6.10 82.40 ± 6.65 0.644 Not 
significant 
 
No Statistically significant difference in diastolic blood pressure was 
noted between the two groups.  
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MEAN ARTERIAL PRESSURE  
MAP Group C n=30 
(Mean ± Standard 
deviation) 
Group M n=30 
(Mean ± Standard 
deviation) 
P 
Value 
Significance 
Base 
line 
93.20 ± 4.64 93.26 ± 5.81 0.968 Not 
Significant 
0 min 88.16 ± 5.00 87.19 ± 5.12 0.462 Not 
Significant 
5 min 91.91 ± 5.16 91.61 ± 4.86 0.817 Not 
Significant 
10 min 94.31 ± 5.51 94.89 ± 4.86 0.668 Not 
Significant 
20 min 94.74 ± 5.63 95.78 ± 4.71 0.444 Not 
Significant 
30 min 93.89 ± 5.68 94.18 ± 4.82 0.833 Not 
Significant 
40 min 95.60 ± 5.73 96.78 ± 4.96 0.398 Not 
Significant 
 
No Statistically significant difference in diastolic blood pressure was 
noted between the two groups.  
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OXYGEN SATURATION 
 
SPO2 Group C n=30 Group M n=30 P Value 
Base line 98.6 ± 1.192 98.43 ± 1.104 0.576 
0 min 99 ± 0 99 ± 0 - 
5 min 99.07 ± 0.785 99.27 ± 0.74 0.314 
10 min 99.1 ± 0.885 98.87 ± 0.73 0.270 
20 min 99.2 ± 0.805 98.97 ± 0.85 0.280 
30 min 99.1 ± 0.845 98.93 ± 0.868 0.454 
40 min 99.1 ± 0.803 99.3 ± 0.702 0.309 
P value <0.05 (Significant) 
There was no statistically significant difference in the oxygen 
saturation status between two groups during the study. 
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Modified Ramsay Sedation score 
 
 
 
Statistically significant difference observed in the Modified Ramsay 
sedation scale between the two groups.  Clonidine found to have significantly 
lesser sedation than magnesium at the time of extubation.  
 
 
  
Study 
Group 
N Score 
Range 
Mean ±  
Standard 
Deviation 
P Value Significance 
C 30 3-4 3.10 ± 0.31  
0.003 
Significant 
M 30 3-4 3.43 ± 0.50 
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Adverse effects 
 
Adverse effects Group C Group M 
No % No % 
Bradycardia 2 7 0 0 
Hypotension 0 0 0 0 
Nausea  0 0 0 0 
Vomiting 0 0 0 0 
Total 30 100 30 100 
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DISCUSSION 
 Laparoscopic surgeries are being performed more and more 
frequently now a days for various elective procedures.  Though Open 
procedures are being done, laparoscopy is preferred by both the patients and 
surgeon for its advantages.  So there is a need for the better control of 
hemodynamics intraoperatively in these type of surgeries.   
 Various pharmacological agents have been studied in the recent 
past for attenuating the hemodynamic responses to the laparoscopy.  Most 
of the studies have compared the effect of intravenous clonidine or 
magnesium with that of the control.  Very few studies are available that 
compare intravenous clonidine with magnesium for attenuation of the 
hemodynamic responses to laparoscopy. 
 So, we have planned for a prospective, randomized, double 
blinded study in Thanjavur Medical College, Thanjavur to compare the 
effect of intravenous clonidine and magnesium on hemodynamic response 
in patients undergoing laparoscopic surgeries.  
 
Patient Characteristics across the group 
 The demographic characteristics like age, weight, ASA status of 
the study population and duration of the surgery were similar in both the 
two groups, with no statistically significant difference. The mean age in 
Clonidine group was 40.23 ± 10.76 years and in Magnesium group was 
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43.10 ± 11.51 years. The mean weight in Clonidine group was 59.10 ± 13.21 
kg and in Magnesium group was 60.42 ± 12.22 kg.  The patients belonged 
to either ASA 1 or ASA 2, and were comparable in both groups. The mean 
duration of the surgery in clonidine group was 53.10 ± 5.88 minutes and in 
Magnesium group was 52.87 ± 4.64 minutes.  
 
Dosage of the drug 
 In Group C we have used clonidine 1.5µg/kg in 50ml normal 
saline and in Group M magnesium sulfate 50mg/kg in 50ml of normal saline 
was used.  The test drug solution were infused over a period of 15 minutes 
before pneumoperitoneum. 
 In the study by Nand Kishore Kalra et al29 compared the 
attenuation of hemodynamic response during laparoscopic cholecystectomy 
due to pneumoperitonem was infused with intravenous clonidine 1 μg/kg, 
clonidine 1.5 μg/kg, magnesium 50mg/kg and placebo and found that both 
clonidine doses and magnesium had significant attenuation on hemodynmic  
stress response when compared with placebo.  The test drugs solution were 
infused after intubation for 15 minutes.  Clonidine 1.5µg/kg showed 
statistically significant difference with magnesium 50mg/kg with no 
incidence of adverse events like bradycardia and hypotension.  
 Similarly Altan and Turgut et al4 used clonidine 3 μg/kg 
intravenously over a period of 15 minutes before induction and then 2 
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μg/kg/min by continuous infusion intraoperatively.  They observed 
significant incidences of bradycardia and hypotension in their study. Ray et 
al 34. used 3 μg/kg of clonidine intravenously over a period of 15 min before 
induction and then 1 μg/kg/min by continuous infusion during surgery and 
observed significant incidences of bradycardia and hypotension in their 
study.  Therefore, we reduced the dose of clonidine, given before 
pneumoperitoneum, to 1.5µg/kg.  Even though we reduced the dose of 
clonidine and avoided the intraoperative infusion, we observed 7% 
incidence of bradycardia in clonidine group patients. 
 Jee et al35 administered magnesium sulfate 50 mg/kg over 2-3 
minutes, before pneumoperitoneum in patients undergoing laparoscopic 
cholecystectomy and observed that it effectively attenuated the 
hemodynamic stress response due to pneumoperitoneum without any 
episode of severe hypotension or bradycardia.  We used same dose of 
magnesium sulfate in our study to compare it with clonidine. The 
magnesium dose selected by us resulted in a steady and smooth reduction of 
mean arterial pressure and heart rate, with no episodes of hypotension and 
bradycardia. 
 Similarly, Paul S et al37 studied the effects of magnesium in 
hemodynamic response to laparoscopic surgery and concluded that the 
mean arterial pressure and heart rate were significantly less throughout the 
period of pneumoperitoneum in patients who received magnesium 30mg/kg 
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when compared with placebo. Telci L et al38 also concluded that the 
administration of magnesium led to a significant reduction in the 
requirements of anaesthetic drugs during total intravenous anaesthesia with 
propofol, remifentanil and vecuronium with better control of 
hemodynamics.  Elsharnouby and Elsharnouby et al used MgSO4 40 mg/ 
kg intravenously over a period of 15 minutes before induction and then 15 
mg/kg/hour by continuous infusion intraoperatively. They noticed episodes 
of severe hypotension while using this dose of MgSO4.  
 In our study, we avoided infusion of magnesium sulfate and we 
did not observe any incidence of hypotension.  Rather, we used slightly 
higher dose of magnesium (50 mg/kg) than Elsharnouby and Elsharnouby 
et al. 
 
Hemodynamic stability 
 Various studies have demonstrated the hemodynamic stability 
with the use of intravenous clonidine and magnesium for laparoscopic 
surgeries. 
 The variation in hemodynamic parameters like heart rate, systolic 
blood pressure, diastolic blood pressure and mean arterial blood pressure 
was observed in the following intervals; baseline, after infusion of test 
drug(P0), 5 minutes after pneumoperitoneum(P5), 10 minutes after 
pneumoperitoneum(P10),  20 minutes after pneumoperitoneum(P20), 30 
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minutes after pneumoperitoneum(P30) and 40 minutes after 
pneumoperitoneum(P40).  
Heart rate  
 Nand Kishore Kalra et al29 observed that statistically significant 
decrease in heart rate in patients who received clonidine 1.5µg/kg  at the 
following intervals; 30 minutes after pneumoperitoneum (P <0.05) and 40 
minutes after pneumoperitoneum (P <0.05) than magnesium 50mg/kg  
group.  There was no statistically significant difference in heart rate between 
the clonidine 1.5µg/kg and magnesium 50mg/kg. This is in contrast with our 
study. 
 A Altan et al4 observed that there was no statistically significant 
difference in heart rate was observed between the patients who received 
clonidine 3µg/kg bolus followed by 2µg/kg/hr  infusion, and magnesium 
sulphate 30mg/kg as a bolus followed by 10mg/kg/hr infusion. This is 
similar to our study. 
 Ray et al34 used clonidine 3µg/kg and then 1µg/kg continuous 
infusion during intraoperative period and observed significant incidences of 
bradycardia and hypotension. Based on these observations we reduced the 
dose of clonidine and did not give infusion to avoid bradycardia and 
hypotension.  We observed no significant variations in the heart rate 
between the groups. 
 Sushil Kumar Nayek infused clonidine 1.5µg/kg inravenously 
80 
 
over a period of 15 minutes before induction followed by 1 µg/kg/hr 
continuous infusion.  They observed that statistically significant decrease in 
heart rate, after induction (P <0.05), 1 minute after intubation (P <0.01), 
zero minutes (P <0.01), 15 minutes (P <0.05), 30 minutes (P <0.05), 45 
minutes (P <0.05) and 60 minutes after pneumoperitoneum (P <0.05). This  
is in contrast to our study. 
 R.Uma et al30 infused clonidine 3µg/kg 15 minutes prior to 
intubation and observed that statistically significant decrease in heart rate in 
clonidine group prior to induction (P-0.005) and 10 minutes after 
pneumoperitoneum (P- 0.015) than the placebo group. This is in contrast 
with our study. 
 Similarly Manjaree Mishra et al7 and Sudheer Rao et al 31 
observed significantly decreased heart rate in clonidine group. A Altan et 
al4 observed significant decreased in heart rate in clonidine group.   
 In our study, there was no statistically significant variations in 
heart rate observed between the two groups at any intervals. 
 
Systolic blood pressure 
 Nand Kishore Kalra et al29 observed that statistically significant 
reduction in systolic blood pressure in patients who received clonidine 
1.5µg/kg at 10 minutes (P <0.05) and 30 minutes after pneumoperitoneum 
(P <0.01) than magnesium 50mg/kg  group.  This is in contrast with our 
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study. 
 A Altan et al 4 observed that there was no statistically significant 
difference in systolic blood pressure observed between the patients who 
received clonidine 3µg/kg bolus followed by 2µg/kg/hr infusion and 
magnesium sulphate 30mg/kg as a bolus followed by 10mg/kg/hr infusion. 
This study is similar to our study result. 
 Deepshikha C Tripathi et al 39 observed that the patients received 
clonidine 2µg/kg showed statistically significant reduction in systolic blood 
pressure changes at 20 minutes after pneumoperitoneum (P <0.05) than the 
placebo group. This is in contrast with our study.  
 Jee et al 35 conducted a study in which patients received 
magnesium sulphate 50mg/kg, infused immediately before 
pneumoperitoneum, showed statistically significant decrease in diastolic 
blood pressure at 10 minutes (P <0.05), 20 minutes (P <0.05) and 30 minutes 
after pneumoperitoneum (P <0.05) than the placebo group. This is in 
contrary to our study. 
 In our study, there was no statistically significant variations in 
systolic blood pressure observed between the two groups at any intervals. 
 
Diastolic blood pressure  
 Nand Kishore Kalra et al29 observed that statistically significant 
reduction in diastolic blood pressure in patients who received clonidine 
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1.5µg/kg  at 30 minutes (P <0.05) and 40 minutes after pneumoperitoneum 
(P <0.01) than magnesium 50mg/kg  group.  This is in contrast to our study. 
  A Altan et al4 observed that there is no statistically significant 
difference in diastolic blood pressure observed between the patients who 
received clonidine 3µg/kg bolus followed by 2µg/kg/hr  infusion, and 
magnesium sulphate 30mg/kg as a bolus followed by 10mg/kg/hr infusion. 
This is similar to our study. 
 Deepshikha C Tripathi 39 et observed that the patients who 
received 2µg/kg showed statistically significant diastolic blood pressure at 
20 minutes after pneumoperitoneum (P <0.05) than the placebo group. This 
result is in contrast with our study. 
 Jee et al 35 conducted a study in which patients received 
magnesium sulphate 50mg/kg, infused immediately before 
pneumoperitoneum, showed statistically significant decrease in diastolic 
blood pressure at 10 minutes (P <0.05), 20 minutes (P <0.05) and 30 minutes 
after pneumoperitoneum (P <0.05) than the placebo group. This is contrary 
to our study. 
 In our study, there was no statistically significant variations in 
diastolic blood pressure observed between the two groups at any intervals. 
 
Mean arterial blood pressure 
 R.Uma et al 30 infused clonidine 3µg/kg 15 minutes prior to 
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intubation and observed that statistically significant decrease in mean 
arterial blood pressure in clonidine group at the following intervals; prior to 
induction (P-0.005), before pneumoperitoneum (P- 0.025), 10 minutes after 
pneumoperitoneum (P- 0.000) and 20 minutes after pneumoperitoneum (P- 
0.000) than the placebo group. This is in contrast with our study. 
 A Altan et al4  observed that there was no statistically significant 
difference in mean arterial blood pressure observed between the patients 
who received clonidine 3µg/kg bolus followed by 2µg/kg/hr  infusion, and 
magnesium sulphate 30mg/kg as a bolus followed by 10mg/kg/hr infusion. 
This is similar to our study. 
 Manjeree Mishra et al observed that the patient who received 
clonidine 1.5µg/kg showed a statistically significant difference in mean 
arterial pressure at the following intervals; 5 minutes after 
pneumoperitoneum (P- 0.037) , 10 minutes after pneumoperitoneum (P 
<0.001), 15 minutes after pneumoperitoneum (P- 0.006) and 20 minutes, 25 
minutes, 30 minutes, 35 minutes  and 40 minutes pneumoperitoneum (P 
<0.01). This is contrary to our study. 
 Suhrita paul et al 37 compared magnesium sulphate 30mg/kg and 
placebo. There is a statistically significant decrease in mean arterial blood 
pressure observed in the magnesium group in the following intervals; 15 
minutes after pneumoperitoneum (P <0.05), 30 minutes after 
pneumoperitoneum (P <0.05) and  30 minutes after pneumoperitoneum (P 
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<0.05). This is in contrast to our study. 
 Similarly, Hayashi et al. and Sung et al. have also concluded that 
clonidine provided better perioperative hemodynamic stability during 
laparoscopic cholecystectomy. Laisalmi, et al. has also reported that 
clonidine premedication blunts the stress response of surgery and reduces 
the requirement of narcotics and anesthetic agent. These are in contrast to 
our study. 
 All the studies done to compare the effect of clonidine and 
magnesium to blunt the stress response to pneumoperitoneum were done in 
laparoscopic cholecystectomy.  But in our study both laparoscopic 
appendicectomy and laparoscopic cholecystectomy were included.  In 
laparoscopic cholecystectomy the positioning is the head up tilt, where as in 
laparoscopic appendicectomy trendelenburg position was used, which is in 
contrast each other. 
 The effect of positioning on the hemodynamics during laparoscopy and 
its influence on the result of studies is not addressed in various studies. 
 In our study, there was no statistically significant variations in 
mean arterial blood pressure observed between the two groups at any 
intervals. 
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Level of sedation  
Both clonidine and magnesium produces sedation.  In our study, we 
compared the sedative effect of clonidine and magnesium by using the 
modified ramsay sedation scale at the time of extubation.  We observed that 
27 patients out of 30 in the clonidine group had a score of 3 (90%) and 3 
patients had a score  of 4 (10%).  But in the magnesium group out of 30 
patients, 18 patients had a score of 3 (60%) and rest of the 12 patients had the 
score of 4 (40%).  This difference in sedative effect could be explained by the 
prolonged sedative effect of magnesium than clonidine.  The p value is <0.003 
and found to be statistically significant. 
Nand K et at29  also concluded that patients receiving magnesium for 
attenuation of hemodynamic stress response showed that time to respond to 
verbal command like eye opening was not statistically significant between the 
clonidine group and magnesium group.  This is in contrast with our study. 
 Javaherfroosh F et al43 conducted a study to observe the effects of 
clonidine to reduce the post-operative nausea and vomiting in laparoscopic 
gynecological surgery.  They found that the Ramsay sedation score is <3 
(P<0.05) in 31/43 (72%) patients and >3 (P<0.05) in 12/43 (28%) patients 
and found to be statistically significant. This is similar to our study result. 
 Eduardo Tocchetto Lemes et al44 conducted a study to observe effects 
of preoperative intravenous clonidine in the surgical treatment of cataract. 
They observed that the patients who received clonidine showed small increase 
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in the degree of sedation at 30 minutes after the surgery when compared with 
placebo group.  This is similar to our study result. 
 Abass Sedighinejad et al 45 conducted a study to compare 
magnesium Sulfate and sufentanil for Patient-Controlled Analgesia in 
Orthopedic Surgery.  They concluded that the magnesium group showed no 
significant difference in sedation score with sufentanil.  However, in our 
study there is significant difference between the clonidine and magnesium 
sulfate. 
  
Adverse effects    
 In our study we observed for the adverse effects like bradycardia, 
hypotension, post-operative nausea, vomiting and shivering, due to 
laparoscopy.  In clonidine group we observed episodes of bradycardia in 2 
out of 30 patients (7%). None other patients had any adverse effects. In the 
magnesium group no patients had any adverse effects. 
Nand K et al29 used clonidine 3 µg/kg and magnesium 50mg.kg 
intravenously over a period of 15 minutes.  They observed no incidences of 
bradycardia and hypotension in their study.  This is in contrast with our study. 
 Altan and Turgut et al 4 used clonidine 3 μg/kg intravenously over a 
period of 15 min before induction and then 2 μg/kg/min by continuous 
infusion intraoperatively.  They observed significant incidences of 
bradycardia and hypotension in their study.  This is similar to our study. 
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 Ray et al34  used 3 μg/kg of clonidine intravenously over a period of 
15 min before induction and then 1 μg/kg/min by continuous infusion during 
surgery and observed significant incidences of bradycardia and hypotension 
in their study.  This is similar to our study. 
 Suhrita Paul et al 37 conducted a study to observe the effects of 
magnesium sulphate on hemodynamic response to carbon dioxide 
pneumoperitoneum in patients undergoing laparoscopic cholecystectomy. 
They observed the hypotension in magnesium group. But in our study we 
did not observe any hypotension in any of the group. 
 Javaherfroosh F et al43 conducted a study to observe the effects of 
clonidine to reduce the post-operative nausea and vomiting in laparoscopic 
gynecological surgery. They concluded that the clonidine group patients had 
reduced incidence of nausea and vomiting than placebo group. This is in 
contrast to our study. 
 Eduardo Tocchetto Lemes et al44 conducted a study to observe 
effects of preoperative intravenous clonidine in the surgical treatment of 
cataract.  They found that the clonidine group patients had hypotension and 
bradycardia.  This is in contrast to our study. 
 Nand Kishore Kalra et al 29 compared the effect of clonidine 
versus magnesium in attenuating the stress response to laparoscopy showed 
that clonidine is superior to magnesium in blunting the hemodynamic 
response to pneumoperitoneum.  Nand Kishore kalra et al study has been 
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done on laparoscopic cholecystectomies, where the head up position is used.  
In our study majority of cases were laparoscopic appendicectomy in both 
clonidine and magnesium group. 
 A greater fall in the systolic blood pressure, diastolic blood 
pressure and mean arterial pressure in clonidine group over magnesium 
group was observed in laparoscopic cholecystectomy only, where as in our 
study majority of cases were laparoscopic appendicectomy cases, in which 
trendelenburg position was used.  The enhanced effect of clonidine over 
magnesium in attenuation the systolic blood pressure, diastolic blood 
pressure and mean arterial pressure to pneumoperitoneum is probably offset 
by the head down tilt or trendelenburg position used in laparoscopic 
appendicectomy.  So, our study shows that clonidine and magnesium are 
equally effective in attenuating the stress response to pneumoperitoneum. 
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SUMMARY 
 
 We conducted a prospective double blinded randomized control study 
in 60 patients belonging to ASA I and II undergoing elective laparoscopic 
surgeries in Thanjavur medical college.  Patients of both sexes ranging 
between 20 to 60 years of age were included.  Our aim was to evaluate and 
compare the effect of intravenously administered clonidine 1.5µg/kg and 
magnesium sulfate 50mg/kg for attenuating the hemodynamic responses 
during laparoscopic surgeries.   
Patients were divided randomly using closed cover technique into two 
groups of 30 each.  Group C received clonidine 1.5µg/kg in 50 ml of normal 
saline.  Group M received magnesium 50mg/kg in 50 ml of normal saline.  
 The test drug solution was given after intubation and before 
pneumoperitoneum.  The heat rate, systolic blood pressure, diastolic blood 
pressure, mean arterial pressure, oxygen saturation, adverse effects and level 
of sedation assessed by Modified Ramsay sedation score were noted in both 
groups. 
 The categorical data collected were analyzed by Chi Square test and 
nominal data are analyzed by One-Way ANOVA.  The results were obtained 
in the form of range, mean and standard deviation.  The probability value ‘P’ 
of less than 0.05 was considered statistically significant. 
 In both magnesium and clonidine groups, there was no statistically 
significant differences observed in heat rate, systolic blood pressure, diastolic 
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blood pressure, mean arterial pressure and oxygen saturation in our study.  
However, the level of sedation in clonidine group is less than that of  
magnesium and found to be statistically significant. 
 The patients were observed for adverse effects like bradycardia, 
hypotension, postoperative nausea, vomiting, and shivering.  In clonidine 
group, we observed bradycardia in 7% of patients only.  
 From our study, we concluded that clonidine 1.5 µg/kg was equally 
effective as magnesium 50mg/kg in blunting the hemodynamic stress 
response during laparoscopic surgeries and clonidine had lesser sedation than 
magnesium at extubation. 
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CONCLUSION 
 Intravenous administration of clonidine 1.5µg/kg before 
pneumoperitoneum is as effective as intravenous magnesium sulfate 
50mg/kg before pneumoperitoneum in blunting the haemodynamic stress 
responses during laparoscopic surgeries and clonidine has lesser sedation 
than magnesium at extubation. 
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PROFORMA 
COMPARATIVE STUDY OF INTRAVENOUSLY ADMINISTERED 
CLONIDINE AND MAGNESIUM SULFATE ON HEMODYNAMIC 
RESPONSES DURING LAPAROSCOPIC SURGERIES 
Name : IP No : 
Age : Yrs Sex : Male/Female Weight : Kgs 
ASA : I/II/III/IV MPG : I/II/III/IV 
Diagnosis : Procedure : 
Duration  : Group:       C / M  
Pre-Operative examination 
Pulse rate : /min BP :  mmHg SpO2:     %  
CVS :  RS :   
Intra Operative period 
Parameter Baseline 0 mins 5 mins 10 mins 20 mins 30 mins 40 mins 
HR        
MAP        
SpO2        
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Level of sedation at the time of extubation ( Modified Ramsay sedation score) 
Score Level of activity 
0 Paralyzed, unable to evaluate 
1 Awake 
2 Lightly sedated 
3 Moderately sedated, follows simple commands 
4 Deeply sedated, responds to non-painful stumuli  
5 Deeply sedated, responds only to painful stimuli 
6 Deeply sedated, unresponsive to painful stimuli 
 
Post Operative Period  
Nausea  
Vomiting 
Shivering 
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KEY TO MASTER CHART 
ASA American Society of Anaesthesiologist  
F (Sex) Female 
C(Study group) Clonidine 
M(Study group) Magnesium 
HR Heart rate 
MAP Mean arterial blood pressure 
SPO2 Oxygen Saturation  
ETCO2 End tidal carbondioxide 
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Base line After infusion(P0) 5 mins(P5) 10 mins(P10) 20 mins(P20) 30 mins(P30) 40  mins (P40) 
 
 
                                    
1 Harikrishnan  43 M 55 Appendectomy 1 (C) Clonidine 50 89 117 74 88 98 58 108 65 79 99 85 112 67 82 99 87 117 69 85 99 85 113 70 84 99 86 115 69 84 98 89 134 71 92 100  3 Bradycardia 
2 Golistan 38 M 53 Appendectomy 1 (C) Clonidine 60 101 127 88 101 100 98 120 80 93 99 101 123 82 96 100 103 126 83 97 98 100 124 86 99 98 104 125 85 98 98 107 127 87 100 100  4 Nil 
3 Mary 39 F 51 Cholecystectomy 2 (C) Clonidine 44 94 108 76 87 98 92 104 71 82 99 93 105 74 84 99 94 108 75 86 100 91 107 76 86 100 92 108 73 85 100 94 113 75 88 100  3 Nil 
4 Seetha 41 F 74 Appendectomy 2 (C) Clonidine 58 96 111 89 96 99 95 108 83 91 99 99 112 88 96 99 102 116 89 98 98 99 111 91 98 99 100 113 89 97 100 101 113 90 98 98  3 Nil 
5 Kavitha 24 F 40 Appendectomy 2 (C) Clonidine 54 93 117 89 98 100 86 113 88 96 99 90 122 90 101 100 92 128 93 105 100 91 126 95 105 99 93 128 92 104 100 94 131 94 106 98  4 Nil 
6 Sumathi 25 F 68 Appendectomy 1 (C) Clonidine 59 91 130 81 97 100 84 126 80 95 99 88 132 82 99 98 90 136 85 102 99 89 134 87 103 100 92 136 85 102 100 93 138 87 104 100  3 Nil 
7 Lakshmi 57 F 76 Appendectomy 2 (C) Clonidine 56 89 122 82 95 99 88 121 76 91 99 89 123 81 95 99 92 127 82 97 98 90 122 83 96 99 94 123 82 96 99 96 111 83 92 99  3 Nil 
8 Rajeswari 27 F 68 Appendectomy 2 (C) Clonidine 45 76 112 87 95 100 71 105 78 87 99 74 115 81 92 98 76 117 82 94 98 74 116 85 95 100 75 117 83 94 100 77 118 85 96 98  3 Nil 
9 Arivendran 59 M 54 Cholecystectomy 1 (C) Clonidine 58 98 122 77 92 100 94 113 68 83 99 95 115 72 86 100 98 119 73 88 100 97 114 74 87 98 100 115 71 86 98 103 126 73 91 99  3 Nil 
10 Chitra 41 F 72 Appendectomy 2 (C) Clonidine 52 78 111 86 94 100 76 102 79 87 99 81 111 84 93 98 83 117 87 97 99 81 115 89 98 98 85 116 87 97 100 86 122 88 99 99  3 Nil 
11 Kalaivani 53 F 41 Cholecystectomy 2 (C) Clonidine 56 80 128 74 92 98 73 119 72 88 99 77 127 75 92 100 78 130 78 95 100 75 129 80 96 99 76 130 79 96 98 78 114 81 92 98  3 Nil 
12 Nageswaran 60 M 48 Cholecystectomy 2 (C) Clonidine 49 73 109 82 91 98 65 102 77 85 99 70 105 78 87 98 72 109 79 89 100 69 105 82 90 100 70 106 81 89 98 73 119 82 94 99  3 Nil 
13 Krishnaveni 37 F 71 Appendectomy 2 (C) Clonidine 53 97 121 82 95 97 93 120 81 94 99 96 123 82 96 99 97 125 84 98 99 94 121 87 98 100 97 122 86 98 98 99 125 88 100 99  4 Nil 
14 Nandhini 37 F 49 Appendectomy 2 (C) Clonidine 60 80 107 85 92 100 75 98 82 87 99 76 99 85 90 100 78 100 86 91 98 77 97 87 90 100 81 99 84 89 100 82 101 85 90 100  3 Nil 
15 Moovendar 45 M 77 Appendectomy 1 (C) Clonidine 43 102 122 86 98 99 94 115 77 90 99 56 116 80 92 100 100 122 83 96 100 97 120 85 97 98 100 121 82 95 98 102 123 83 96 99  3 Bradycardia 
16 Kamalam 44 F 44 Appendectomy 2 (C) Clonidine 59 90 129 71 90 98 86 122 69 87 99 90 127 73 91 98 92 128 75 93 98 90 127 76 93 99 91 128 73 91 100 93 129 74 92 100  3 Nil 
17 Hansika 36 F 78 Cholecystectomy 2 (C) Clonidine 48 93 116 77 90 97 90 109 75 86 99 94 111 80 90 99 96 114 83 93 100 94 110 84 93 99 97 112 82 92 99 99 100 83 89 98  4 Nil 
18 Sudha 55 F 76 Cholecystectomy 2 (C) Clonidine 60 84 109 89 96 100 83 108 82 91 99 87 109 87 94 100 88 111 89 96 100 87 108 92 97 98 90 109 91 97 100 91 131 92 105 99  3 Nil 
19 Vijaya 49 F 41 Appendectomy 2 (C) Clonidine 53 100 112 78 89 97 95 105 74 84 99 98 113 79 90 100 100 114 82 93 100 97 112 85 94 100 100 113 82 92 99 103 138 84 102 100  3 Nil 
20 Saravanan 34 M 64 Appendectomy 1 (C) Clonidine 54 107 121 85 97 98 99 116 83 94 99 103 119 86 97 98 106 123 88 100 99 103 119 90 100 100 107 120 87 98 99 108 111 88 96 100  3 Nil 
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21 Arokiyasamy 50 M 41 Cholecystectomy 1 (C) Clonidine 58 90 126 84 98 97 82 125 78 94 99 87 134 82 99 100 90 139 85 103 100 87 134 87 103 99 88 135 86 102 100 89 118 87 97 99  3 Nil 
22 Rajalingam 20 M 51 Cholecystectomy 2 (C) Clonidine 49 108 126 89 101 97 100 124 82 96 99 104 130 83 99 99 105 133 85 101 100 102 132 88 103 100 106 133 87 102 98 107 126 89 101 98  3 Nil 
23 Silambarasan 35 M 65 Appendectomy 1 (C) Clonidine 60 85 115 73 87 98 78 109 68 82 99 81 112 71 85 99 82 113 73 86 100 81 112 76 88 99 83 114 73 87 99 85 126 74 91 98  3 Nil 
24 Dhanalakshmi 45 F 65 Appendectomy 2 (C) Clonidine 44 72 112 82 92 100 71 111 80 90 99 74 118 84 95 99 75 120 87 98 99 72 118 88 98 98 75 119 86 97 98 77 122 87 99 99  3 Nil 
25 Mayakrishnan 37 M 75 Cholecystectomy 1 (C) Clonidine 48 74 114 71 85 97 70 109 70 83 99 73 110 75 87 100 74 113 76 88 100 72 110 79 89 98 73 112 77 89 100 75 114 78 90 98  4 Nil 
26 Valli 34 F 52 Appendectomy 2 (C) Clonidine 58 88 125 85 98 100 81 121 79 93 99 83 122 82 95 99 86 125 85 98 99 85 124 86 99 100 88 126 84 98 99 90 119 85 96 100  3 Nil 
27 Kalaiselvi 44 F 47 Appendectomy 1 (C) Clonidine 57 84 108 72 84 99 78 103 68 80 99 81 106 70 82 99 82 109 72 84 98 79 105 74 84 100 83 107 73 84 100 84 134 74 94 100  3 Nil 
28 Kala 43 F 45 Appendectomy 2 (C) Clonidine 45 110 110 75 87 98 109 100 73 82 99 113 107 76 86 98 114 110 78 89 98 112 106 80 89 99 113 108 78 88 99 116 109 80 90 99  3 Nil 
29 Mathini 20 F 73 Appendectomy 2 (C) Clonidine 59 96 124 78 93 99 89 123 72 89 99 94 129 77 94 99 95 133 78 96 98 93 129 80 96 100 96 130 78 95 99 99 133 79 97 99  4 Nil 
30 Maheswari 34 F 52 Appendectomy 1 (C) Clonidine 44 74 111 86 94 97 69 101 77 85 99 75 107 83 91 98 80 108 85 93 98 78 105 89 94 100 81 106 87 93 99 82 110 89 96 100  3 Nil 
31 Thilagavadahi 41 F 40 Appendectomy 1 (M) MgSO4 51 106 108 71 83 98 100 104 67 79 99 103 108 73 85 99 108 112 77 89 99 105 109 81 90 98 109 110 77 88 99 111 114 79 91 99  3 Nil 
32 Rajendran 60 M 46 Appendectomy 1 (M) MgSO4 58 101 115 75 88 97 94 114 68 83 99 98 122 72 89 100 104 123 75 91 99 102 120 77 91 100 103 122 74 90 99 105 124 77 93 100  3 Nil 
33 Farhana 48 F 43 Cholecystectomy 1 (M) MgSO4 52 82 129 70 90 97 75 127 64 85 99 82 133 68 90 100 86 134 72 93 98 82 132 75 94 98 84 133 73 93 100 85 135 76 96 99  3 Nil 
34 Anandavalli 38 F 42 Cholecystectomy 2 (M) MgSO4 50 106 117 75 89 98 104 115 68 84 99 108 123 71 88 100 112 125 73 90 99 110 122 76 91 99 111 123 74 90 98 112 124 77 93 99  4 Nil 
35 Rajalakshmk 45 F 71 Appendectomy 2 (M) MgSO4 47 93 109 84 92 99 85 105 79 88 99 90 114 83 93 98 96 118 85 96 100 94 115 87 96 99 97 116 83 94 100 98 117 85 96 100  3 Nil 
36 Vimal 22 M 60 Appendectomy 1 (M) MgSO4 45 93 126 89 101 97 86 117 79 92 99 92 124 81 95 98 96 128 84 99 99 93 124 86 99 98 97 125 82 96 98 98 127 85 99 100  4 Nil 
37 Annaduari 35 M 78 Cholecystectomy 1 (M) MgSO4 53 74 130 79 96 98 71 122 75 91 99 77 123 77 92 100 81 128 81 97 98 79 127 83 98 99 80 128 80 96 100 81 130 83 99 100  3 Nil 
38 Maheswari 34 F 52 Appendectomy 1 (M) MgSO4 60 87 130 86 101 99 80 126 76 93 99 84 127 80 96 100 90 133 83 100 99 86 129 87 101 99 90 130 85 100 100 92 134 88 103 99 3 Nil 
39 Nandagopal 59 M 63 Appendectomy 1 (M) MgSO4 53 97 116 75 89 98 96 114 65 81 99 102 120 68 85 100 108 126 71 89 100 105 123 74 90 100 108 124 70 88 98 110 127 72 90 100 3 Nil 
40 Roselin thenmozhi 58 F 58 Appendectomy 2 (M) MgSO4 50 98 118 78 91 99 92 108 72 84 99 96 109 77 88 99 102 110 80 90 98 99 109 82 91 100 100 110 79 89 100 101 113 81 92 99 4 Nil 
41 Lalitha 20 F 57 Appendectomy 2 (M) MgSO4 55 77 112 76 88 97 69 102 73 83 99 75 105 75 85 100 80 111 77 88 99 77 107 80 89 99 79 109 78 88 99 81 113 80 91 99 3 Nil 
42 Shanmugavalli 54 F 48 Cholecystectomy 2 (M) MgSO4 58 74 123 89 100 99 67 115 84 94 99 73 121 88 99 99 78 126 91 103 100 76 123 93 103 100 80 125 91 102 99 81 129 94 106 99 4 Nil 
43 Chinnathambi 45 M 78 Cholecystectomy 2 (M) MgSO4 46 108 129 88 102 97 107 119 80 93 99 114 125 82 96 99 119 129 84 99 99 117 128 88 101 98 121 130 84 99 98 123 134 86 102 99 3 Nil 
44 Pavithra 45 F 63 Appendectomy 1 (M) MgSO4 46 92 115 90 98 98 89 108 86 93 99 95 109 92 98 99 99 112 94 100 99 96 107 97 100 100 100 109 95 100 99 102 111 97 102 99 3 Nil 
45 Arulmarrry 36 F 50 Appendectomy 2 (M) MgSO4 49 103 104 72 83 97 95 99 69 79 99 100 108 75 86 99 105 113 78 90 98 101 108 82 91 99 102 110 78 89 98 103 113 80 91 98 3 Nil 
46 Pitchaiammal 22 F 74 Cholecystectomy 2 (M) MgSO4 56 78 127 79 95 99 70 118 72 87 99 74 123 77 92 100 80 125 81 96 99 77 120 85 97 98 81 122 82 95 100 82 126 84 98 100 3 Nil 
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47 Veerammal 40 F 71 Appendectomy 1 (M) MgSO4 59 94 121 80 94 100 90 115 75 88 99 97 116 78 91 99 103 122 80 94 99 100 119 83 95 99 102 121 79 93 100 104 122 82 95 100 4 Nil 
48 Ayisha 34 F 65 Appendectomy 2 (M) MgSO4 55 77 118 89 99 97 71 109 86 94 99 74 114 88 97 99 79 115 90 98 100 77 110 92 98 100 80 111 89 96 98 82 114 92 99 100 3 Nil 
49 Selvanathan 48 M 75 Appendectomy 1 (M) MgSO4 52 98 105 71 82 100 90 104 68 80 99 96 109 73 85 99 102 114 76 89 98 100 113 79 90 100 101 115 75 88 98 103 119 78 92 99 3 Nil 
50 Vinoth kumar 50 M 77 Appendectomy 1 (M) MgSO4 48 108 130 78 95 99 101 129 67 88 99 108 132 71 91 100 113 135 74 94 98 109 130 78 95 99 110 131 74 93 98 111 134 76 95 98 4 Nil 
51 Parameshwari 54 F 44 Cholecystectomy 2 (M) MgSO4 57 92 107 76 86 99 89 104 68 80 99 93 110 71 84 99 97 116 74 88 98 95 113 78 90 98 99 115 76 89 99 100 118 78 91 100 3 Nil 
52 Vijayakumari 60 F 52 Cholecystectomy 2 (M) MgSO4 58 74 118 89 99 100 72 117 81 93 99 79 127 87 100 100 85 132 90 104 100 83 130 92 105 100 86 132 89 103 100 88 136 91 106 100 3 Nil 
53 Rajendran 40 M 55 Appendectomy 2 (M) MgSO4 51 105 127 77 94 100 100 124 73 90 99 105 125 75 92 98 110 127 77 94 98 108 124 80 95 98 109 125 76 92 98 110 129 78 95 98 3 Nil 
54 Ilangovan 33 M 78 Appendectomy 2 (M) MgSO4 45 83 116 77 90 98 79 113 68 83 99 84 123 74 90 100 90 126 78 94 98 88 124 80 95 98 90 125 76 92 99 91 128 78 95 100 3 Nil 
55 Nagammal 29 F 77 Cholecystectomy 2 (M) MgSO4 55 92 111 90 97 98 86 107 79 88 99 93 117 82 94 100 99 119 85 96 99 95 116 89 98 100 97 118 86 97 98 98 122 89 100 99 3 Nil 
56 Sanjeevi 48 M 46 Appendectomy 2 (M) MgSO4 57 107 121 71 88 99 106 115 64 81 99 110 123 67 86 99 116 128 70 89 100 112 126 72 90 98 113 128 68 88 99 115 129 70 90 99 4 Nil 
57 Balasubramanian 59 M 66 Appendectomy 2 (M) MgSO4 54 81 129 74 92 99 74 125 64 84 99 78 135 69 91 98 83 141 72 95 98 80 139 74 96 98 84 141 72 95 100 86 145 75 98 99 3 Nil 
58 Jothimani 50 F 66 Cholecystectomy 2 (M) MgSO4 60 73 124 81 95 100 69 118 77 91 99 75 124 82 96 100 79 129 84 99 99 77 125 86 99 99 80 127 83 98 100 82 131 86 101 98 3 Nil 
59 Nagavenni 37 F 62 Appendectomy 2 (M) MgSO4 49 89 125 87 100 97 88 122 76 91 99 93 130 79 96 99 97 136 83 101 99 95 134 85 101 98 97 136 81 99 98 99 139 83 102 100 3 Nil 
60 Vinothini 49 F 64 Appendectomy 1 (M) MgSO4 57 75 129 86 100 100 68 124 81 95 99 74 126 85 99 98 80 131 89 103 99 76 126 93 104 100 77 127 90 102 98 78 129 92 104 100 4 Nil 
 
 
